Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population

Cesare Cuspidi, Rita Facchetti, Michele Bombelli, Carla Sala, Marijana Tadic, Guido Grassi, Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled. Thus, we evaluated the relationship of SUA with new-onset echocardiographic LVH over a 10-year period in subjects of the general population enrolled in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study.

METHODS: The study included 960 subjects with normal LV mass index (LVMI) at baseline echocardiographic evaluation and a readable echocardiogram at the end of follow-up. Cut-points for LVH were derived from reference values of the healthy fraction of the PAMELA population.

RESULTS: Over a 10-year period, 258 participants (26.9%) progressed to LVH. The incidence of new-onset LVH increased from the lowest (23%) to intermediate (25%) and the highest baseline SUA tertile (32%). After adjusting for confounders (not including body mass index (BMI)), each 1 mg/dl increase in SUA entailed a 26% higher risk of incident LVH. Adjusted odd ratio of LVH risk in the highest SUA tertile was 96% higher than in the lowest tertile (odds ratio (OR) = 1.966, 95% CI = 1.158-3.339, P = 0.0123). Correction for BMI reduced the magnitude and statistical significance of ORs.

CONCLUSIONS: The study shows that SUA is a predictor of long-term echocardiographic changes from normal LVMI to LVH in a community sample. Thus, life-style and pharmacologic measures aimed to reduce SUA levels may concur to preventing LVH development in the general population.

Original languageEnglish
Pages (from-to)279-285
Number of pages7
JournalAmerican Journal of Hypertension
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Left Ventricular Hypertrophy
Uric Acid
Population
Serum
Body Mass Index
Odds Ratio
Aptitude
Life Style
Reference Values
Incidence

Keywords

  • Journal Article

Cite this

Uric Acid and New Onset Left Ventricular Hypertrophy : Findings From the PAMELA Population. / Cuspidi, Cesare; Facchetti, Rita; Bombelli, Michele; Sala, Carla; Tadic, Marijana; Grassi, Guido; Mancia, Giuseppe.

In: American Journal of Hypertension, Vol. 30, No. 3, 01.03.2017, p. 279-285.

Research output: Contribution to journalArticle

Cuspidi, Cesare ; Facchetti, Rita ; Bombelli, Michele ; Sala, Carla ; Tadic, Marijana ; Grassi, Guido ; Mancia, Giuseppe. / Uric Acid and New Onset Left Ventricular Hypertrophy : Findings From the PAMELA Population. In: American Journal of Hypertension. 2017 ; Vol. 30, No. 3. pp. 279-285.
@article{726257f49c36422595f942855d72bd23,
title = "Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population",
abstract = "BACKGROUND: The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled. Thus, we evaluated the relationship of SUA with new-onset echocardiographic LVH over a 10-year period in subjects of the general population enrolled in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study.METHODS: The study included 960 subjects with normal LV mass index (LVMI) at baseline echocardiographic evaluation and a readable echocardiogram at the end of follow-up. Cut-points for LVH were derived from reference values of the healthy fraction of the PAMELA population.RESULTS: Over a 10-year period, 258 participants (26.9{\%}) progressed to LVH. The incidence of new-onset LVH increased from the lowest (23{\%}) to intermediate (25{\%}) and the highest baseline SUA tertile (32{\%}). After adjusting for confounders (not including body mass index (BMI)), each 1 mg/dl increase in SUA entailed a 26{\%} higher risk of incident LVH. Adjusted odd ratio of LVH risk in the highest SUA tertile was 96{\%} higher than in the lowest tertile (odds ratio (OR) = 1.966, 95{\%} CI = 1.158-3.339, P = 0.0123). Correction for BMI reduced the magnitude and statistical significance of ORs.CONCLUSIONS: The study shows that SUA is a predictor of long-term echocardiographic changes from normal LVMI to LVH in a community sample. Thus, life-style and pharmacologic measures aimed to reduce SUA levels may concur to preventing LVH development in the general population.",
keywords = "Journal Article",
author = "Cesare Cuspidi and Rita Facchetti and Michele Bombelli and Carla Sala and Marijana Tadic and Guido Grassi and Giuseppe Mancia",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/ajh/hpw159",
language = "English",
volume = "30",
pages = "279--285",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Uric Acid and New Onset Left Ventricular Hypertrophy

T2 - Findings From the PAMELA Population

AU - Cuspidi, Cesare

AU - Facchetti, Rita

AU - Bombelli, Michele

AU - Sala, Carla

AU - Tadic, Marijana

AU - Grassi, Guido

AU - Mancia, Giuseppe

PY - 2017/3/1

Y1 - 2017/3/1

N2 - BACKGROUND: The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled. Thus, we evaluated the relationship of SUA with new-onset echocardiographic LVH over a 10-year period in subjects of the general population enrolled in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study.METHODS: The study included 960 subjects with normal LV mass index (LVMI) at baseline echocardiographic evaluation and a readable echocardiogram at the end of follow-up. Cut-points for LVH were derived from reference values of the healthy fraction of the PAMELA population.RESULTS: Over a 10-year period, 258 participants (26.9%) progressed to LVH. The incidence of new-onset LVH increased from the lowest (23%) to intermediate (25%) and the highest baseline SUA tertile (32%). After adjusting for confounders (not including body mass index (BMI)), each 1 mg/dl increase in SUA entailed a 26% higher risk of incident LVH. Adjusted odd ratio of LVH risk in the highest SUA tertile was 96% higher than in the lowest tertile (odds ratio (OR) = 1.966, 95% CI = 1.158-3.339, P = 0.0123). Correction for BMI reduced the magnitude and statistical significance of ORs.CONCLUSIONS: The study shows that SUA is a predictor of long-term echocardiographic changes from normal LVMI to LVH in a community sample. Thus, life-style and pharmacologic measures aimed to reduce SUA levels may concur to preventing LVH development in the general population.

AB - BACKGROUND: The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled. Thus, we evaluated the relationship of SUA with new-onset echocardiographic LVH over a 10-year period in subjects of the general population enrolled in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study.METHODS: The study included 960 subjects with normal LV mass index (LVMI) at baseline echocardiographic evaluation and a readable echocardiogram at the end of follow-up. Cut-points for LVH were derived from reference values of the healthy fraction of the PAMELA population.RESULTS: Over a 10-year period, 258 participants (26.9%) progressed to LVH. The incidence of new-onset LVH increased from the lowest (23%) to intermediate (25%) and the highest baseline SUA tertile (32%). After adjusting for confounders (not including body mass index (BMI)), each 1 mg/dl increase in SUA entailed a 26% higher risk of incident LVH. Adjusted odd ratio of LVH risk in the highest SUA tertile was 96% higher than in the lowest tertile (odds ratio (OR) = 1.966, 95% CI = 1.158-3.339, P = 0.0123). Correction for BMI reduced the magnitude and statistical significance of ORs.CONCLUSIONS: The study shows that SUA is a predictor of long-term echocardiographic changes from normal LVMI to LVH in a community sample. Thus, life-style and pharmacologic measures aimed to reduce SUA levels may concur to preventing LVH development in the general population.

KW - Journal Article

U2 - 10.1093/ajh/hpw159

DO - 10.1093/ajh/hpw159

M3 - Article

C2 - 28096148

VL - 30

SP - 279

EP - 285

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 3

ER -